Industry Insights
Talking NGS, Liquid Biopsies and Tumor Mutational Burden With Luca Quagliata
Industry InsightWe recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific. Previously, Quagliata was involved in one of the first teams in Europe to introduce Next Generation Sequencing (NGS) in routine molecular diagnostics. Here, he shares his perspectives on the field, particularly the use of NGS in the analysis of liquid biopsies, the discovery of cancer biomarkers and the potential application of artificial intelligence (AI) in molecular diagnostics.
Read More
Single Cell Analysis – Advantages, Challenges, and Applications
Industry InsightWe recently spoke with Dr Marian Rehak, VP of Research and Development at Sphere Fluidics, to learn more about the importance of single cell analysis. Marian touches on some of the common challenges encountered and highlights some of the key applications.
Read More
Agilent’s Latest Acquisition in the Cell Analysis Space: BioTek Instruments
Industry InsightAgilent Technologies Inc. recently announced it had signed an agreement to acquire BioTek Instruments, a global leader in life science instrumentation.
Read More
Size Matters: Diffusion Technique Sorts Out Pathological Proteins
Industry InsightProteinopathies are diseases that feature misfolded proteins. In the brain, proteinopathies are rife, but research techniques are facing up to the challenge of studying these diseases. We talked to the University of Cambridge’s Tom Scheidt, whose research uses an innovative technique called diffusional sizing to better understand proteins.
Read More
Fentanyl Analogue Identification Toolkit Aids Forensic Toxicology
Industry InsightGetting an arrow in the target is hard enough but imagine trying to do it when the target is constantly moving or morphs into something that doesn’t even look like the target anymore? This is the challenge for forensic scientists trying to detect fentanyl in samples. We spoke to research scientist Alex Krotulski about his group’s arms race with the evolution of fentanyl variants.
Read More
Waters’ Highly Flexible SYNAPT XS Offers Freedom of Analytical Choice
Industry InsightA highly flexible and high-resolution mass spectrometer, the SYNAPT™ XS technology from Waters has been developed with the analytical needs of R&D labs in mind. Joanne Ballantyne tells us more about the development of SYNAPT™ XS and the features to which it lends its versatility.
Read More
NRGene Are Taking Agricultural Research to the MAX
Industry InsightNRGene recently announced the launch of DeNovoMAX, an enhanced version of its flagship product DeNovoMAGIC, for whole genome assembly. As part of the DeNovo assembly product suite, DeNovoMAX aims to take agricultural research further by empowering breeding and maximizing agricultural yield. We spoke with Gal Ramot, Marketing Director at NRGene Ltd to learn about the applications of DeNovoMAX and how it has been built to crack the most "complex of genomes".
Read More
Pharma-backed Toolkit to Speed Up Adoption of FAIR Data Principles
Industry InsightFAIR is a set of data principles that hopes to form a gold standard for scientific data management. Non-profit the Pistoia Alliance has developed a toolkit to help companies adopt FAIR. We spoke to Pistoia's Ian Harrow to find out more.
Read More
Therapeutically Targeting DYRK1A in Alzheimer’s Disease
Industry InsightAlzheimer’s disease (AD) is a neurodegenerative condition. There are currently no FDA-approved disease‐modifying therapies for AD, despite it being the most common cause of dementia. We recently spoke with Samumed’s CEO Osman Kibar, to learn more about the company's efforts to therapeutically target "DYRK1A" in AD.
Read More
Identifying Novel Opioid Agonists From Metabolites
Industry InsightNovel drugs of abuse have been a growing problem for law enforcement and the medical profession. Consequently, they have also become a challenge for analysts in the face of new or variant chemicals. We spoke to Research Scientist Alex Krotulski about the work he is doing to identify new and emerging illicit substances.
Read More
